Sugi Predict

Sugi Predict / Compounds / SCHEMBL3708745

SCHEMBL3708745

SCHEMBL3708745

C[C@@H](C(=O)O)N(C)C(=O)CCCCCN1C(=O)C=CC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 7/20 0.56
▸ PTGS2 P35354 7/20 0.56
▸ MGLL Q99685 7/20 0.47
▸ FAAH O00519 5/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ TLR9 Q9NR96 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ GPR35 Q9HC97 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3708749 1.00 PTGS1 (0.56) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL15836347 0.91 PTGS1 (0.47) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL21018458 0.87 PTGS1 (0.57) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL22424790 0.86 PTGS1 (0.54) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL22424754 0.86 PTGS1 (0.54) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL15836343 0.83 PTGS1 (0.47) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL31045339 0.81 PTGS1 (0.48) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL17222831 0.81 PTGS1 (0.37) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL21909660 0.81 PTGS1 (0.64) PTGS1PTGS2MGLLFAAHALDH1A1
SCHEMBL12327492 0.80 PTGS1 (0.49) PTGS1PTGS2MGLLFAAHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428477-B2 Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same ANGIEX, INC. (US) 2025-09-30 — — US disclosed
US-20250152730-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. 2025-05-15 — — US disclosed
EP-4536290-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME Angiex, Inc. (US) 2025-04-16 — — EP disclosed
WO-2023239803-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2023-12-14 — — WO disclosed
US-20230338572-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. 2023-10-26 — — US disclosed
EP-4188449-A2 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME Angiex, Inc. (US) 2023-06-07 — — EP disclosed
US-20230096824-A1 ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING THE SAME ANGIEX, INC. 2023-03-30 — — US disclosed
WO-2022026915-A9 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2022-04-28 — — WO disclosed
WO-2022026915-A2 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2022-02-03 — — WO disclosed
EP-2640727-B1 ALANINYL MAYTANSINOL ANTIBODY CONJUGATES GENENTECH INC (US) 2015-05-13 — — EP disclosed
US-8889855-B2 Preparation of maytansinoid esters Bio-Thera Solutions Ltd., Co. (CN) 2014-11-18 — — US disclosed
US-8889855-B2 Preparation of maytansinoid esters Bio-Thera Solutions Ltd., Co. (CN) 2014-11-18 — — US disclosed
US-20140179917-A1 PREPARATION OF MAYTANSINOID ESTERS BIO-THERA SOLUTIONS, LTD., CO. (CN) 2014-06-26 — — US disclosed
US-20140179917-A1 PREPARATION OF MAYTANSINOID ESTERS BIO-THERA SOLUTIONS, LTD., CO. (CN) 2014-06-26 — — US disclosed
WO-2014094354-A1 PREPARATION OF MAYTANSINOID ESTERS BIO-THERA SOLUTIONS, LTD. (CN) 2014-06-26 — — WO disclosed
US-20120121615-A1 ALANINYL MAYTANSINOL ANTIBODY CONJUGATES GENENTECH, INC. 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428477-B2 Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same TM9SF4, TM9SF2, TM9SF3 PTGS1 4681/4885PTGS2 4706/4885MGLL 3722/4885
US-20230096824-A1 ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING THE SAME TM9SF4, TM9SF2, TM9SF3 PTGS1 4681/4885PTGS2 4706/4885MGLL 3722/4885
US-20230338572-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME TM9SF4, TM9SF2, TMPRSS4 PTGS1 4447/4885PTGS2 4553/4885MGLL 3778/4885
US-20120121615-A1 ALANINYL MAYTANSINOL ANTIBODY CONJUGATES MTX2, FOLH1, MGAT3 PTGS1 2409/4885PTGS2 2171/4885MGLL 1322/4885
US-20140179917-A1 PREPARATION OF MAYTANSINOID ESTERS WEE1, WEE2, CRH PTGS1 3505/4885PTGS2 4117/4885MGLL 611/4885
US-20250152730-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME TM9SF4, TM9SF2, TMPRSS4 PTGS1 4429/4885PTGS2 4548/4885MGLL 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.